Spectral AI, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ryan Zimmerman from BTIG maintained a Buy rating on the stock and has a $3.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ryan Zimmerman has given his Buy rating due to a combination of factors, despite some short-term setbacks. The company reported lower-than-expected revenue and earnings for the third quarter of 2025, primarily due to the timing of work on a government contract and the impact of a government shutdown. However, these issues are expected to be mitigated in the following fiscal year, with significant revenue anticipated upon FDA clearance of their DeepView system.
Additionally, Spectral AI is on track with key milestones, including the submission of regulatory filings to the FDA and the planned spin-off of its IP subsidiary. The company is also progressing with the development of a miniaturized version of its DeepView system, aimed at military and commercial applications. Despite the current financial challenges, the long-term growth prospects, particularly with the commercial launch of DeepView, support the Buy rating, as revenue is expected to grow significantly in the coming years.